{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:57:32Z","timestamp":1791849452823,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Journal Armed Forces India"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/s0377-1237(06)80155-3","type":"journal-article","created":{"date-parts":[[2011,6,23]],"date-time":"2011-06-23T13:51:44Z","timestamp":1308837104000},"page":"45-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment"],"prefix":"10.1016","volume":"62","author":[{"given":"AC","family":"Anand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AK","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0377-1237(06)80155-3_bib1","series-title":"WHO report, 2001","first-page":"287","article-title":"Global Tuberculosis Control","year":"2001"},{"key":"10.1016\/S0377-1237(06)80155-3_bib2","first-page":"595","article-title":"Hepatitis and antitubercular therapy","volume":"39","author":"Mahashur","year":"1991","journal-title":"J Assoc Physicians India"},{"issue":"3","key":"10.1016\/S0377-1237(06)80155-3_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00004836-199604000-00012","article-title":"Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy","volume":"22","author":"Singh","year":"1996","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/S0377-1237(06)80155-3_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0002-9343(84)90697-1","article-title":"Short course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampicin: community physicians' seven-year experience with mainly outpatients","volume":"77","author":"Dull","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/S0377-1237(06)80155-3_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1378\/chest.99.2.465","article-title":"Hepatitis with isoniazid and rifampicin; a meta-analysis","volume":"99","author":"Steele","year":"1991","journal-title":"Chest"},{"key":"10.1016\/S0377-1237(06)80155-3_bib6","first-page":"278","article-title":"Study on hepatotoxicity and other side effects of antituberculosis drugs","volume":"88","author":"Taneja","year":"1990","journal-title":"J Indian Med Assoc"},{"key":"10.1016\/S0377-1237(06)80155-3_bib7","first-page":"58","article-title":"Lack of relationship between hepatic toxicity and acerylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis","volume":"129","author":"Gurumurthy","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/S0377-1237(06)80155-3_bib8","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1164\/rccm.2108091","article-title":"Evaluation of Clinical and Immunogenetic Risk Factors in the Development of Hepatotoxicity during Antituberculosis Treatment","volume":"166","author":"Sharma","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/S0377-1237(06)80155-3_bib9","first-page":"599","article-title":"Anti-tubercular treatment in patients with hepatitis","volume":"39","author":"Deshpande","year":"1991","journal-title":"J Assoc Physicians India"},{"issue":"12","key":"10.1016\/S0377-1237(06)80155-3_bib10","first-page":"1538","article-title":"Liver dysfunction related to Anti-tuberculous treatment is more common in chronic hepatitis","volume":"50","author":"Anand","year":"2002","journal-title":"JAssocPhysicians India"},{"key":"10.1016\/S0377-1237(06)80155-3_bib11","first-page":"1","article-title":"BMI and mortality rate-a 10 year prospective study","year":"1989","journal-title":"National Institute of Nutrition Annual Report"},{"issue":"6","key":"10.1016\/S0377-1237(06)80155-3_bib12","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1345\/aph.1D525","article-title":"Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors","volume":"38","author":"Shakya","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/S0377-1237(06)80155-3_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/thx.51.2.132","article-title":"Risk factors for hepatotoxicity from antituberculous drugs: a case control study","volume":"51","author":"Pande","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/S0377-1237(06)80155-3_bib14","first-page":"963","article-title":"Isoniazid. rifampicin and hepatotoxicity","volume":"133","author":"Gangadharan","year":"1986","journal-title":"Am J Respir Dis"},{"key":"10.1016\/S0377-1237(06)80155-3_bib15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/pgmj.71.836.359","article-title":"Antituberculosis treatment induced hepatotoxicity: role of predictive factors","volume":"71","author":"Singh","year":"1995","journal-title":"Postgrad Med J"},{"key":"10.1016\/S0377-1237(06)80155-3_bib17","first-page":"461","article-title":"Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis","volume":"118","author":"Gronhagen-Riska","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/S0377-1237(06)80155-3_bib18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0016-5085(90)90846-S","article-title":"Isoniazid-rifampin induced hepatitis in hepatitis B carriers","volume":"98","author":"Wu","year":"1990","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/S0377-1237(06)80155-3_bib19","first-page":"666","article-title":"Isoniazid prophylaxis in hepatitis B carriers","volume":"134","author":"McGlynn","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/S0377-1237(06)80155-3_bib20","first-page":"133","article-title":"Hepatitis in patients with surgical complications of pulmonary tuberculosis","volume":"33","author":"Ansari","year":"1991","journal-title":"Indian J Chest Dis Allied Sci"},{"key":"10.1016\/S0377-1237(06)80155-3_bib21","first-page":"299","article-title":"Isoniazid pharmacokinetics in kwashiorkor","volume":"56","author":"Buchanan","year":"1979","journal-title":"S Afr Med J"},{"key":"10.1016\/S0377-1237(06)80155-3_bib22","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1164\/ajrccm\/143.6.1350","article-title":"Hepatotoxicity of rifampicin and isoniazid: is it all drug induced hepatitis?","volume":"143","author":"Kumar","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/S0377-1237(06)80155-3_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0016-5085(19)32568-5","article-title":"Isoniazid-asscciated hepatitis in 114 patients","volume":"69","author":"Black","year":"1975","journal-title":"Gastroenterology"},{"key":"10.1016\/S0377-1237(06)80155-3_bib24","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1164\/ajrccm\/140.3.700","article-title":"Twenty isoniazid-associated deaths in one state","volume":"140","author":"Moulding","year":"1989","journal-title":"Am Rev Respir Dis"},{"issue":"12","key":"10.1016\/S0377-1237(06)80155-3_bib25","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1086\/375072","article-title":"Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity","volume":"36","author":"Kunimoto","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0377-1237(06)80155-3_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-79-1-1","article-title":"Isoniazid hepatitis","volume":"79","author":"Maddrey","year":"1973","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/S0377-1237(06)80155-3_bib27","first-page":"995","article-title":"Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics","volume":"6","author":"Lee","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"10.1016\/S0377-1237(06)80155-3_bib28","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-137-8-200210150-00007","article-title":"Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial","volume":"137","author":"Jasmer","year":"2002","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/S0377-1237(06)80155-3_bib29","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/S0377-1237(06)80155-3_bib30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1378\/chest.123.1.102","article-title":"Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity","volume":"123","author":"McNeill","year":"2003","journal-title":"Chest"},{"issue":"4","key":"10.1016\/S0377-1237(06)80155-3_bib16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/jhep.2003.50144","article-title":"Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis","volume":"37","author":"Huang","year":"2003","journal-title":"Hepatology"}],"container-title":["Medical Journal Armed Forces India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123706801553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123706801553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:38:52Z","timestamp":1759837132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0377123706801553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0377123706801553"],"URL":"https:\/\/doi.org\/10.1016\/s0377-1237(06)80155-3","relation":{},"ISSN":["0377-1237"],"issn-type":[{"value":"0377-1237","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment","name":"articletitle","label":"Article Title"},{"value":"Medical Journal Armed Forces India","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0377-1237(06)80155-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Director General, Armed Forces Medical Services. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}